Key Takeaways
- Base business delivers, Cenexi drags: Consolidated revenue grew 16% YoY, but the core injectables business (ex-Cenexi) posted 14% growth with stable ~29% EBITDA margins, while Cenexi's consolidation pulled consolidated EBITDA margin down to 19% from 25% a year ago.
- U.S. sequential dip is noise, not signal: The 14% QoQ U.S. revenue decline is 8% milestone/licensing income from Q4 not repeating, 2% lower quantity, and product mix dilution from a new heparin GPO contract; management calls it temporary and expects normalisation over the next few quarters.
- Heparin margin dilution is a one-quarter event: A new GPO contract nearly doubled heparin volumes, but at ~25-30% contribution margin, this compressed gross margin; the initial four-month stock build ends, so dilution normalises from Q2.
- Biologics CDMO momentum is real but early: The Genome Valley facility is attracting advanced-stage interest, and a collaboration for large-scale contract manufacturing of four biosimilars is in early-stage discussions, with the Biosecure Act driving more inbound interest to India as a second manufacturing base.
- What to watch next quarter: Whether Cenexi's Q2 revenue (guided to two-thirds of Q1 on shutdowns) keeps its EBITDA-positive Q4 target credible, the pace of heparin margin normalisation, and any clarity on the biologics collaboration.
Cenexi Turnaround: Progress, Pain & Timeline
- Revenue trending up, losses narrowing: Cenexi revenue rose 7% sequentially, with gross margin recovering to its historical 78% level; operating cost leverage and efficiency efforts are reducing losses.
- Fontenay site improvements are tangible: Higher volumes shipped, reduced backlog, additional weekend shifts, organisational changes, optimised production planning, and maintenance reorganisation all contributed to the improved performance.
- Q2 will be a step back by design: A 3-4 week shutdown in Q2 (August holiday season, planned maintenance, plus extended 3-week shutdown at Fontenay for new ampoule line installation) means Q2 revenue is expected at roughly two-thirds of Q1 levels.
- The shutdown carries a capacity payoff: The downtime is being used to install a new high-speed line; the incremental impact beyond the normal annual two-week maintenance break is only one week.
- New lines add revenue from early 2025: The Fontenay ampoule line is expected to generate approximately €10 million in revenue in 2025; the Hérouville aseptic gel line begins commercial production for a key customer before year-end.
- Turnaround is still quarters away: Management is explicit that a complete turnaround is not imminent, though the target remains positive EBITDA for Q4 of this fiscal year and for the full next fiscal year, driven by revenue crossing the €200 million threshold.
Srinivas Sadu: "While we remain optimistic about the opportunity, I must inform all of you that Cenexi is still a few quarters away from a complete turnaround."
U.S. Market: The Quarter-by-Quarter Noise
- Underlying volume demand is healthy: U.S. revenue grew 27% YoY, with volumes up almost 30% versus the prior year, driven by existing product share gains and new launches including Eribulin, Plerixafor, Nelarabine, and Edaravone.
- The QoQ decline unpacks into three pieces: 8 percentage points from milestone and licensing revenue on complex products recognised in Q4 FY24 that did not repeat; 2 percentage points from slightly lower quantity (a capacity constraint on a couple of brands, not demand); and product mix dilution from heparin.
- Heparin is a low-value, high-volume product: When a new GPO contract starts, roughly four months of stock is supplied upfront, nearly doubling volumes this quarter; contribution margin on heparin is only ~25-30%, so the mix shift compressed both gross and EBITDA margins. This normalises from Q2 onward.
- The annual U.S. target remains intact: Management confirmed that on an annual basis, the U.S. is still on track to meet what was envisaged at the beginning of the year.
- Front-end strategy is under evaluation: The hybrid model of potentially going front-end on own in the U.S. is still on the table, but management says it is too early to comment.
Srinivas Sadu: "If you compared to the last year, the volume wise it's gone up by almost 30%. But if you see the previous quarter, the quantity, you can't really compare, it's almost the same, I think, gone down by 2% U.S., but it's more to do with how many batches can make on those lines. And it's more a capacity situation on a couple of brands, which impacted us a bit."
Biologics CDMO: Early Innings, Real Optionality
- The Biosecure Act is driving inbound interest: Management confirmed that more companies are looking at India as a second manufacturing base to derisk their supply chains, directly benefiting CDMOs in the space.
- Genome Valley facility attracting advanced-stage interest: Multiple players are in discussions for contract manufacturing of monoclonal antibodies and novel plasma-based proteins.
- A named collaboration is in early-stage talks: A leading biologics company is discussing large-scale contract manufacturing of four biosimilars, with a possible in-licensing opportunity for Gland in specific markets. The discussion involves investment to increase capacities, backed by CDMO contracts and commercial volumes.
- Clarity is expected soon, but not immediate: Management expects to provide more clarity on the commercial benefit and structure of the biologics collaboration in about a quarter.
- Complex products pipeline is building: Six complex products have been filed so far, with one suspension product filed last quarter.
Srinivas Sadu: "For sure, I just mentioned, I think that also is result of this, I would say, because I think we are seeing more inbounds than compared to before. And they're looking India as a second base for a lot of companies to have to derisk themselves. So, I would say that it would benefit CDMOs in this space."
India & Rest of World: Strategic Resets
- India decline is deliberate: The 19% revenue decrease reflects a strategic decision; management is evaluating options for the path forward and does not intend to scale up domestic business unless a dedicated facility can be found, because using the same facility for India compromises overall economics.
- Rest of world is lumpy but growing annually: The 3% revenue decrease reflects tender-led procurement delays from partners that shifted to subsequent months; management expects healthy growth on an annual basis.
Margins: The Two-Speed Story
- Base business margins are stable: Ex-Cenexi, EBITDA margin held at ~29% versus 30% a year ago, and base business PAT grew 20%.
- Consolidated margin compression is all Cenexi: Consolidated EBITDA margin fell to 19% from 25% YoY, driven by Cenexi's negative EBITDA consolidation and, this quarter, the heparin mix effect on gross margin.
- Heparin dilution normalises from Q2: The initial four-month stock build for the new GPO contract ends, so the ~25-30% contribution margin product stops being an outsized share of the mix.
- Milestone income is high-margin but lumpy: Milestone and licensing revenue is not 100% gross margin but largely so; the 6-percentage-point gap in milestone contribution between Q4 and Q1 affected both gross and EBITDA margins.
- Cash flow improved sharply: Cash flow from operations rose to ₹427.7 crore from ₹62.9 crore, driven by a reduction in the cash conversion cycle from 233 days to 148 days through inventory reduction.
Regulatory & Capacity: Quiet Progress
- Two surprise U.S. FDA inspections concluded: The Dundigal site received two Form 483 observations and Pashamylaram received three; management described them as procedural and not affecting compliance status.
- Cenexi capacity expansion underway: A new ampoule line at Fontenay will be commissioned during the August shutdown, with commercial production in early 2025; a new aseptic gel line at Hérouville begins commercial production before year-end.
- Acquisition focus is on complex injectables and difficult-to-make small molecules: Management sees two areas for inorganic investment: R&D-heavy complex injectable opportunities, and building manufacturing capabilities further into difficult-to-make products. In the long term, more organic capacity may be needed for U.S. and rest-of-world growth.
Alain Kirchmeyer: "This line will be commissioned during the summer shutdown period of August, with commercial production slated to begin in early 2025. We anticipate this new line will significantly increase capacity, improve customer service, and generate approximately €10 million in revenue in 2025."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Base business revenue growth | Mid-teens growth for full year (ex-Cenexi) | FY25 |
| Base business EBITDA margin | Around 32-33% | FY25 |
| Cenexi EBITDA breakeven | Positive EBITDA | Q4 FY25 |
| Cenexi full-year EBITDA | Positive EBITDA for the full fiscal year | FY26 |
| Cenexi revenue threshold | Revenue exceeding €200 million to drive EBITDA positivity | FY26 |
| Cenexi Q2 revenue | Approximately two-thirds of Q1 FY25 revenue level | Q2 FY25 |
| Heparin margin normalisation | Dilution from initial stock build normalises | Starting Q2 FY25 |
| U.S. annual performance | On track to meet beginning-of-year target | FY25 |
| Fontenay ampoule line revenue | Approximately €10 million | Calendar 2025 |
| Biologics collaboration clarity | More clarity on commercial benefit and structure | ~1 quarter |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Consolidated revenue | ₹1,401.7 cr, +16% YoY |
| Base business revenue (ex-Cenexi) | ₹1,013.4 cr, +14% YoY |
| Consolidated gross margin | 60%, vs 63% in Q1 FY24 |
| Consolidated EBITDA | ₹265.4 cr, -11% YoY |
| Consolidated EBITDA margin | 19%, vs 25% in Q1 FY24 |
| Base business EBITDA margin | 29%, vs 30% in Q1 FY24 |
| Consolidated net profit | ₹143.8 cr, -26% YoY |
| Consolidated PAT margin | 10% |
| Base business PAT growth | 20% YoY |
| U.S. market revenue growth | 27% YoY |
| Core markets revenue share | 76% of total revenue, 25% YoY growth |
| Rest of world markets revenue share | 20% of total revenue, -3% YoY |
| India market revenue share | 4% of total revenue, -19% YoY |
| Cenexi revenue | ₹388.3 cr (€43 mn), +7% QoQ |
| Cenexi gross margin | 78%, improved to historical level |
| Cenexi EBITDA | -₹28.6 cr (-€3 mn) |
| R&D expenditure | ₹48.9 cr, 5% of base business revenue |
| ANDAs filed during quarter | 8 filed, 7 approved |
| Total ANDA status (as of Jun 30, 2024) | 356 filed, 295 approved, 61 pending |
| Product registrations worldwide | 1,708 |
| Cash and equivalents (group level) | ₹3,048.8 cr as of Jun 30, 2024 |
| Net cash position | ₹2,743 cr, including Cenexi loans |
| Cash flow from operations | ₹427.7 cr for three months ending Jun 30, 2024, vs ₹62.9 cr in same period last year |
| Average cash conversion cycle | 148 days, vs 233 days in previous period |
| Capital expenditure | ₹63.7 cr in current fiscal year |
| Base business full-year revenue growth guidance | Mid-teens |
| Base business full-year EBITDA margin guidance | 32%–33% |
| Cenexi EBITDA guidance | Positive EBITDA for Q4 FY25 and positive EBITDA for next fiscal year |
| New Fontenay ampoule line expected revenue | ~€10 mn in 2025 |